- Home
- ASMB vs APLT Comparison
ASMB vs APLT Comparison
Compare ASMB & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- APLT
- Stock Information
- Founded
- ASMB 2005
- APLT 2016
- Country
- ASMB United States
- APLT United States
- Employees
- ASMB N/A
- APLT N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- APLT Health Care
- Exchange
- ASMB Nasdaq
- APLT Nasdaq
- Market Cap
- ASMB 139.8M
- APLT 44.0M
- IPO Year
- ASMB 2010
- APLT 2019
- Fundamental
- Price
- ASMB $18.75
- APLT $0.41
- Analyst Decision
- ASMB Strong Buy
- APLT Buy
- Analyst Count
- ASMB 3
- APLT 7
- Target Price
- ASMB $33.00
- APLT $6.10
- AVG Volume (30 Days)
- ASMB 43.5K
- APLT 2.6M
- Earning Date
- ASMB 08-07-2025
- APLT 08-06-2025
- Dividend Yield
- ASMB N/A
- APLT N/A
- EPS Growth
- ASMB N/A
- APLT N/A
- EPS
- ASMB N/A
- APLT N/A
- Revenue
- ASMB $32,154,000.00
- APLT $265,000.00
- Revenue This Year
- ASMB $0.04
- APLT $1,768.13
- Revenue Next Year
- ASMB N/A
- APLT $292.85
- P/E Ratio
- ASMB N/A
- APLT N/A
- Revenue Growth
- ASMB 148.33
- APLT N/A
- 52 Week Low
- ASMB $7.75
- APLT $0.30
- 52 Week High
- ASMB $19.93
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ASMB 65.84
- APLT 58.87
- Support Level
- ASMB $18.01
- APLT $0.32
- Resistance Level
- ASMB $18.99
- APLT $0.36
- Average True Range (ATR)
- ASMB 0.84
- APLT 0.04
- MACD
- ASMB -0.05
- APLT 0.01
- Stochastic Oscillator
- ASMB 84.42
- APLT 94.92
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.